UNDERWRITING AGREEMENT Aligos Therapeutics, Inc. [•] Shares of Common StockUnderwriting Agreement • June 28th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 4th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of ________ __, 20__ by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of October, 2020, by and among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 25th, 2023 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023 (the “Effective Date”), among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”).
ALIGOS THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 12th, 2024 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Matthew McClure (“Executive”) and Aligos Therapeutics, Inc. (the “Company”), effective as of December 1, 2020 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into effective as of February 10, 2021 (the “Effective Date”), by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”) and Leonid Beigelman, Ph.D. (the “Executive”).
ALIGOS THERAPEUTICS, INC. May 14, 2019Confirmatory Employment Letter • May 10th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (“Agreement”) is entered into between Julian Symons (“you”) and Aligos Therapeutics, Inc. (the “Company” or “we”), effective as of October 16, 2018 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
EMPLOYMENT AGREEMENTEmployment Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is entered into effective as of August 16, 2018 (the “Effective Date”), by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”) and Lawrence M. Blatt, Ph.D. (the “Executive”).
CONSULTING AGREEMENTConsulting Agreement • August 5th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This CONSULTING Agreement is made and entered into as of June 17, 2021 (the “Effective Date”) by and between Aligos Therapeutics, Inc., a Delaware corporation having a principal place of business at 1 Corporate Drive, 2nd Floor, South San Francisco, CA 94080 (“Aligos”) and Kathleen Sereda Glaub, an individual with an address of 1050 Lee Avenue, San Leandro, CA 94577 (“Consultant”). Aligos and the Consultant may be referred to herein individually as “Party” or collectively, as “Parties.”
ALIGOS THERAPEUTICS / EMORY UNIVERSITY LICENSE AGREEMENT OF JUNE 26, 2018License Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (the “Agreement”) is entered into and made effective as of June 26, 2018, (the “Effective Date”) by and between Emory University ( “Emory”), a Georgia nonprofit corporation with offices at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080.
LICENSE AGREEMENTLicense Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (the “Agreement”) is entered into and made effective as of December 19, 2018, (the “Effective Date”) by and between Luxna Biotech Co., Ltd. (“Luxna”), a Japanese corporation having its principal place of business at 3-21-1 Onoharanishi, Mino-City, Osaka 562-0032 Japan, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080.
SUMMARY OF BASIC LEASE INFORMATIONLease • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
AMENDMENTLicense Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances)
Luxna Biotech Co., Ltd. (“Luxna”) and Aligos Therapeutics, Inc. (“Aligos”) agree to amend their License Agreement dated as of December 19, 2018 (“License Agreement”), as follows:
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • March 12th, 2024 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SEPARATION AND GENERAL RELEASE AGREEMENT (this “Agreement”) is made and entered into as of the Effective Date, defined in Section 6(e) below, by and between, Leonid Beigelman, Ph.D., an individual (the “Employee”), and Aligos Therapeutics, Inc., a Delaware Corporation (the “Company”) (collectively the “Parties,” and each a “Party”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”), effective as of June 18, 2020 (“Effective Date”), is entered into between Emory University (“Emory”), a Georgia nonprofit corporation with offices at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 156 2nd Street, Suite 403, San Francisco, California 94105 (each individually a “Party” and collectively the “Parties”), and amends that certain Aligos Therapeutics / Emory University License Agreement of June 26, 2018 between the Parties (the “License Agreement”). Capitalized terms used herein without definition shall have the meaning set forth in the License Agreement.
